Both superantigens (SAG) and many anti-TCR monoclonal antibodies (mAb) have specificity for the V[3 region of the TCR encoded by TCRBV genes. For instance the bacterial SAG staphylococcal enterotoxin E (SEE), the retroviral SAG MTV-9 and the mAb OT145 each react with human T cells expressing BV6S7. This BV gene encodes two common alleles. We found that SEE and the mAb preferentially activate T cells expressing BV6S7"1 as opposed to BV6S7"2, but Mtv-9 activates T cells expressing either allele. Thus binding to the TCR differs between the two SAGs. A mutation in the TCR HVR-4 region of BV6S7"1 (G72E), where the two BV6S7 alleles differ, indicated that HVR-4 is a component of the binding site for SEE and for the mAb OT145. BV6S7"2 has a charged E72 which may result in electrostatic repulsion of SEE, as SEE contains a similarly acidic aspartic acid residue at a TCR interaction site (204D).
S
uperantigens are powerful T cell mitogens produced by bacteria, mycoplasma and certain viruses. In contrast to nominal peptide antigens they do not require antigen processing and presentation to T cells is not restricted to individual MHC alleles. However, efficient presentation does require binding of the superantigens (SAG) 1 to an MHC class II molecule at the surface of an antigen presenting cell. Typically superantigens activate T ceils that express T cell antigen receptors (TCR) using specific BV genes.
The bacterial SAG SEE (1), the retroviral SAG Mtv-9 (2), and the mAb OT145 (3), have each been shown to react with human T ceils expressing BV6S7, previously designated VI36.7 (4) . There are two naturally occurring alleles of this gene, which differ by two nonconservative amino acids substitutions at positions 38 and 72 (4, 5) . BV6S7"1 (V136.7a) encodes $38 (serine) and G72 (glycine) , whereas BV6S7"2 (VI36.7b) encodes R38 (arginine) and E72 (glutamic acid). Position 72 is located in hypervariable region-4 (HVR4) of the TCR {3 chain. HVR-4 is a region of the TCR J3 chain previously implicated in recognition of bacterial and viral SAGs, including SEB, SEC1, SEC2, Mtv-7, and Mtv-9 (6) (7) (8) (9) . Therefore, we tested T cell responses to TAbbreviations used in this paper: RAM, rabbit anti-mouse; SAG, superantigens; SEE, Staphylococcal enterotoxin E. SEE and Mtv-9 SAG to assess whether these SAG distinguish between the two alleles of BV6S7.
In addition to HVR-4 residues, TCR residues outside of HVR-4 have also been shown to influence SAG reactivity (10) (11) (12) (13) (14) . Moreover, the precise topology of the interaction between SAG encoded residues and TCR residues is still unresolved as co-crystals involving SAG and TCR have not yet been described. There is data on the SAG residues involved in interactions with TCR. For instance, the COOH-terminal residues of the Mtv SAGs are polymorphic and therefore thought to be responsible for TCR BV specificity (15, 16) . Several studies have pinpointed two residues on SEE that provide for the TCR BV specificity of this SAG (P203 and D204) (17) (18) (19) . Using these previous results and the data described herein we propose a model of interaction between TCR BV6S7 position 72 with specific residues of SEE and describe relative positions within the trimolecular complex for TCR, superantigen and MHC.
Materials and Methods
Cells and mAbs. Heparinized peripheral blood was obtained from normal donors with known homozygous or heterozygous BV6S7 genotype (4) . Mononuclear cells were isolated by Ficoll Hypaque gradient separation and in some cases T cells were further separated by rosetting with neuraminidase-treated sheep red blood cells. Cell separations with GAM-coated magnetic beads (Immunotech SA, Marseilles, France) were performed as previously described (20) . These separations were monitored by staining before and after the separation. The efficiency of this procedure is ~90%. DAP row-9 is a statJle transfectant expressing HLA-DR1 and the Mtv-9 sag gene cloned in to the expression vector pHAb-Aprl-neo on a mouse DAP fibroblast background. The transfectants were cultured in RPMI-1640 10% fetal bovine serum, 1% L-glutamine, 1% penicillin-streptomycin in the presence of G418. The mAb OT145 is specific for BV6S7 as previously described (4, 21) . Other TCR BV-specific mAbs are described elsewhere (22) . The Jurkat transfectants, YP59.44 and m72, have previously been described (3). Staphylococcal enterotoxin E (SEE) was obtained from Toxin Technology Inc., and used at 0.1 ng/ml.
Cultures. For co-cultures of T cells with Mtv-transfectants, the latter were first treated with mitomycin C, 50 mcg/ml, to stop further proliferation. For other co-cultures irradiated (3,000 rads) autologous non-T cells were pulsed with the superantigens SEE or SEA (1 ng/ml or as indicated), then washed and added back to the autologous T cells at a 1:1 ratio. T cells were preincubated with OT145 ascites (dil. 1:500) for 1 h and then washed and cultured with APCs (irradiated non-T cell fraction from PBMNC). PHA was used at 1 ~g/ml. Cultures were in RPMI 1640, 10% fetal calf serum, 1% penicillin and 1% streptomycin with added glutamine, hlL-2 (50 U/ml; Boehringer Mannheim, Indianapolis, IN) was added after 3-4 d.
Immunofluorescence. One-color and two-color flow cytometric analysis was performed as follows. 2 X 10 ~ cells were first incubated with saturating concentrations of anti-BV mAbs for 40 min on ice in RPMI 1640, 1% fetal bovine serum (FBS). Anti-CD3, anti-CD4, anti-CD8, and the negative control mAb FFa26 were used as controls. After incubation, ceils were washed with RPMI 1640 1% FBS and then stained with goat anti-mouse Ig conjugated to FITC (GAM-FITC; Tago Inc., 1:50 dilution) on ice for 30 rain. After washing, 5,000 cells were analyzed on a Coulter EPICS cytofluorograph (Hialeah, FL). For two-color staining, mAb FFa26 (lgG1) was added for 20 min on ice to block unoccupied binding sites of GAM-FITC antibodies. Cells were washed and then incubated with phycoerythrin-conjugated anti-CD8 or anti-CD4 mAb (Immunotech) for 30 min on ice.
IntracellularCa § Studies. The Jurkat transfectants, YP59.44 and m72, were collected, washed and suspended at 107 cells/ml. The cells were labeled with Indo-1 (Molecular Probes, Eugene, OR) at 5 mM for 1 h at 37~ in the dark. The washed cells were resuspended in PBS, I mM Ca ++, 1 mM Mg § Fluorescence was monitored in a spectrofluorometer. Stimuli were added under continuous stirring of 106 cells in a 0.4 ml volume. For the addition of SEE in the presence of antigen-presenting cells (APCs) the MHC class II positive 8866-P B lymphoblastoid cell line (107 cells) was added at either a 1:1 or a 3:1 cell ratio before addition of SEE.
TCR BV Use by PCR. RNA was isolated using RNAzol B (CINNA/BIOTECX Labs., Houston, TX) and cDNA synthesized with random hexanucleotide primers and m-MLV reverse transcriptase. Primers for BV genes paired with a BC primer were used to amplify cDNA by PCR as described elsewhere (23) . cDNA from PHA-activated normal T cells indicated that all BV primers were able to amplify DNA from the specified subsets (BV1, 2, 3, 4, 5S1, 5S2/3, 6, 7, 8S1, 8S4, 9, 10, 11, 12, 13S1, 13S2, 14, 15, 16, 17, 18, 19, 20) . The BV6 sense primer used, primer I in (4) , is a 19-mer with complete sequence identity with all BV6 genes and nearly all of their allelic variants. The A/T overhang vector PCR2000 was used to subclone PCR products as described elsewhere (24) . Single transformed bacterial colonies were selected for sequencing of the plasmid inserts. Sequencing reactions were performed with sequenase, version 2.0 DNA sequencing kit (United States Biochemical, Cleveland, OH).
PCR to Detect BV6S7 Allele Use. BV6S7"1 contains a BamHI site which is not present in BV6S7"2 (4). Therefore, BV6S7 allele usage was assessed by PCR with primers that straddle the polymorphic BamHI site and by digestion of the PCR product with BamHI as described by Vissinga et al. (25) . RNA was prepared and cDNA synthesized. BV6S7 primers were 5'GTCACA-GAGAAGGGAAAGG3' (sense) and 5'CGGCCGAGTCCT-CCTGCTG3' (anti-sense). These primers yield a 237-bp PCR product. The sense primer was end-labeled with ~/32p ATP using phosphonucleotide kinase (Boehringer Mannheim). The PCR mix contained template cDNA derived from ~50,000 cells, 100 ng of each primer, 2.5 mM MgC1, 0.4 mM dNTPs, 0.8 U Taq polymerase (Promega, Madison, WI) in 50 mM KC1, 10 mM Tris HC1 (pH 9), l{/,} Triton-X. PCR was performed for 30 cycles: 94~ • 1 rain, 60~ X 1 rain, 72~ 5( I rain, with a hot start and a final extension at 72~ • 10 rain. The amplified cDNA was then digested using BamHI (New England Biolabs, Beverly, MA) under optimal conditions, run on a 10% polyacrylamide gel which was exposed to x-ray film. The intact PCR product measures 237 bp (representing BV7S7"2) and the upstream labeled fragment from the BamHI digest measures 189 bp (representing BV6S7"1). The relative intensity of these two bands on exposed x-ray film was assessed with a scanner and the program IMAGE R.
The nomenclature used herein for TCR BV genes is according to the Genbank L36092 entry for the entire TCR BV locus. An alternative nomenclature has recently been proposed in which BV6S7 was designated BV6S5 (26) and Rowen et al. propose the name 7-2 (27) .
Results

SEE
Activates BV6S7"1, but Not BV6S7"I G72E, ExpressingJurkat T Cells. A Jurkat transfectant expressing TCR BV6S7"1 (YP55.49) was compared with a Jurkat transfecrant expressing a mutated TCR BV6S7"1 chain with a substitution in the HVR4 region, G72E. This substitution was chosen because it represents the naturally occurring BV6S7"2 allele which encodes E72. Both transfectants expressed the identical Jurkat derived rearranged TCR A gene (3) . SEE pulsed APC were added to Jurkat cells, loaded with Indo-1, and intracellular Ca § + concentration was measured over time ( Fig. 1) . A Ca + § response was observed with the BV6S7"1 transfectant (YP55.49), but not with the transfectant expressing BV6S7"1 G72E (m72), although both transfectants expressed equivalent levels of TCRcI~ (3) and signaled by increasing intracellular Ca ++ in response to a CD3 mAb. This result suggests that HVR-4 is part of the binding site for SEE presented by class II-positive APCs. Consistent with previous results which showed undetectable binding of the mAb OT145 to m72 cells (3), there was no Ca § response to the OT145 mAb, even in the presence of crosslinking rabbit anti-mouse (RAM) antibodies (Fig. 1) .
MTV-9 Activates T Cells Expressing both BV6S7 Alleles. The viral SAG of Mtv-9 was tested as a stable transfectant in conjunction with human HLA DR1 in mouse fibroblasts (2) . Co-culture of this transfectant with normal hu-
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TCR Binding Differs for SEE and Mtv-9 SAG man T cells results in expansion of the BV6S7 subset which can easily be monitored by staining the T cells with the monoclonal antibody OT145. This is a highly specific BV response, as a survey with a panel of workshop antibodies covering over 60% of the TCII. BV repertoire revealed no other expanded BV subsets in response to Mtv-9 SAG stimulation (28) .
Previous studies had shown that individuals homozygous for BV6S7"2 had very low levels of OT145 positive cells (4, 21) . Together with the poor binding of OT145 to m72 cells (3), this suggested that OT145 preferentially reacts with T cells expressing BV6S7"1.
To determine whether Mtv-9 prefers to react with one or the other allele of BV6S7, cells from two homozygous BV6S7"2 donors and one homozygous BV6S7"1 donor were stimulated with the Mtv-9 transfectant. IL-2 was added on day 3 of culture. On day 10 the T cells were stained by indirect immunofluorescence. As shown in Fig. 2 , T cells from all 3 individuals responded with expansions of OT145 + cells. This demonstrates that the Mtv-9 SAG is capable of stimulating T cells expressing either allele of BV6S7. The fluorescence intensity of the OT145 staining was 5-10-fold greater in the cells derived from donor DNP (homozygous for BV6S7"1) as compared to the two donors homozygous for BV6S7"2. This was reproducible in five experiments and demonstrates the lesser reactivity of OT145 with the product of allele BV6S7"2 (see above). In addition, the magnitude of the response (% OT145 positive T cells) is approximately twofold larger with the BV6S7"1 homozygous cells.
To identify the TCR. BV genes used among the OT145+ T cells responding to Mtv-9 SAG, the activated T cells from the experiment shown in Fig. 2 were separated in to OT145+ and OT145-cells using magnetic beads coated with goat anti-mouse Ig antibody. BV gene usage was assessed by RT-PCR (Fig. 3) . A striking predominance of BV6 message was found in the Mtv-9 SAG activated T cells without other BV genes detectable. The findings were identical for both OT145+ and OT145-cells. However, a semi-quantitative RT-PCR. indicated that there was at BV6 is the largest h u m a n BV family and contains seven functional genes (22, 27) . It was therefore necessary to analyze the PCP, product by sequencing to determine which BV6 genes were utilized. PCP, products amplified with a pan-BV6 and B C (constant region) primer were subcloned and sequenced. W e found that 11/17 sequences from the BV6S7"1 homozygous donor ( O T 1 4 5 + ceils) were BV6S7"1 with unrelated V -D -J junctions and BJ usage (Fig. 4 A) . In contrast, sequences from the homozygous BV6S7"2 donors yielded BV6S7"2 in 13/17 (Fig. 4 C) and 9 / 9 cases (Fig.   4 B) . BV6S7 was less frequently represented in the amplified BV6 sequences derived from O T 1 4 5 -cells. It is possible that T cells using BV6 genes other than BV6S7 can also respond to Mtv-9. These other BV6 genes might include BV6S3, BV6S4, and BV6S5 seen primarily in the O T 1 4 5 -subset (Fig. 4, A -C ) . As the total a m o u n t of BV6 mlq.NA was about 50>( greater in the O T 1 4 5 + subset, transcripts with these alternative BV6 genes must represent a minority of the T cells responding to the M t v -9 SAG. T h e BV sequence data are summarized in Fig. 5 . There are some BV6 genes that are conspicuously absent from the Mtv-9-stimulated cells: BV6S1, BV6S11, BV6S14. As a con- IF 1 dp-3 BV6S7*2 CASE WEGERG TFGSGT BJIS2 OF 1 dp-7 BV6S7*2 CAS TFLGAH NEQFFGPGT BJ2SI OF 1 dp-24 BV6S7"2 CAS NLVA DTQyFGPGT BJ2S3 IF 1 dp-26 BV6S?*2 CAS RGSA GANVLTFGAG S BJ2S6 IF 1 dp-28 BV6S7*2 CASE FRWD ETQYFGPGT BJ2S5 IF 1 dp-32 BV6S7"2 CAS TRTSGGG GELFFGEGS BJ2S2 IF 1 dp-30 BV6S4 CASS SIQT NSPLHFGNGT BJIS6 IF 1 dp-31 BV6S4 CASS FRY TGELFFGEGS BJ2S2 IF 1 dp-4 BV6S4 CA RYLALG YNQPQHFGDGT BJIS5 IF 1 dp-6 BV6S4 CASS PLDV ETQYFGPGT BJ2S5 IF 1 dp-i BV6S3 CASE TGQGG TGELFFGEGS BJ2S2 IF 1 dp-23 BV6S3 CASSL TG TNEKLFFGSGT BJIS4 IF 2 dp-27 BV6S3 _ASS TSQVT NYGYTFGSGT BJIS2 OF 1 dp-22 BV6SI CASE SIH~D TEAFFGQGT BJISI IF 1 trol for variations in P C R efficiency, some of these sequences could readily be amplified from genomic D N A . Moreover, an additional antibody specific for BV6S1 (22) failed to stain Mtv-9-activated T cells (28) . In unrelated studies effects of BJ encoded (14) or V-D-J junctional encoded (13) amino acids on SAG reactivity have been uncovered. However, BJ usage was equally distributed among BV6S7 and other BV6 T C R s in all three donors tested with only a few possible exceptions: BJ1S6 was used by 0/44 BV6S7 sequences, but 5/30 other BV6 sequences, and BJ2S6 was used by 3/44 BV6S7 sequences, but 0/30 other BV6 sequences (Table 1 ). There is no amino acid motif from the V-D-J or the J region that is shared exclusively by BV6S7 sequences and not other BV6 sequences (Fig. 4) and it seems unlikely that the minor difference in BJ usage reflects preferences of the SAG.
SEE and 0TI45 mAb Each Preferentially Activate the B V6S7* 1 Allele.
To distinguish between reactivity preferences of the SAGs and o f the mAb OT145, an experimental system was needed that did not rely on OT145 staining or sorting and in which cells expressing both BV6S7 alleles were present. Therefore, T cells from BV6S7 heterozygous donors were stimulated with either SEE, Mtv-9 SAG or OT145 and cultured with IL-2 for 10 d. Expansion of T cells using BV6S7"1 versus BV6S7"2 was then measured by R T -P C R with two BV6S7-specific primers, of which the upstream primer was end-labeled with 32p (the amplified fragment is 237 bp). The P C R product of the BV6S7"1 allele contains a BamHI site. After BamHI digestion the labeled upstream fragment (189 bp) migrates faster (Fig. 6 ). To control for partial BamHI digestion, P C R amplified D N A from a BV6S7"1 homozygous donor was used (DNP, Fig. 6 A) . Mtv-9 and P H A stimulation of T cells from a heterozygous donor (SF) resulted in expression of both BV6S7 alleles (Fig. 6 A) . By contrast, OT145 stimulation led to a marked shift to BV6S7"1 expression.
To assess the effect of SEE in this system, BV8 positive T cells need first he removed, as this BV subset is the preferred target of SEE (29) . Effects of SEE on BV6S7 T cells
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TCR Binding Differs for SEE and Mtv-9 SAG On day 10 the cells were washed and a second culture was initiated with the additives listed. On day 17 the cells were stained (Fig. 6 B) and R N A was harvested for R T -P C R (Fig. 6 C) . At this time each culture contained an expanded subset of O T 1 4 5 + cells (Fig. 6/3 ) but BV8 expressing cells were undetectable (not shown). BV6S7 allele usage was not skewed in cells stimulated with Mtv-9 or with the control SAG SEA (Fig. 6 C) . SEE used at two different concentrations favored expression of BV6S7"1. Fig. 1 , we conclude from these data that both SEE and OT145 react preferentially with allele "1.
Position 72 of TCR BV6S7 Lies in Close Proximity to Residues 203-204 of SEE.
Previous work has identified two adjacent positions in SEE and SEA that impart specificity for BV encoded regions (17) (18) (19) . Thus, BV specificity was exchanged between SEE and SEA by replacing only 2-3 residues in an exposed loop between 13 strand 10 and oL helix 5 (18) . Therefore we used SEE D197G P203S D204N (D19), which has acquired the specificity or SEA, and SEA $206P N207D (C19) with the acquired specificity of SEE, to see whether BV6S7 cells were stimulated and whether there was a preference for either allele of BV6S7. Fig. 6 D demonstrates that SEA and D19 gave less stimulation of BV6S7 cells as indicated by low intensity P C R bands and lower percentage of O T 1 4 5 + cells by FACS | (data not shown). Both alleles of BV6S7 were equally represented. By contrast SEE and C19 were more stimulatory and levels ofBV6S7*I R N A were predominant over BV6S7"2 in 3/3 experiments. C19 usually showed even greater preference for allele "1 than SEE itself.
These results indicate that the ability to discriminate between G72 and E72 of the T C R [3 chain H V R -4 lies in residues P203 and D204 of SEE (Fig. 7) . Therefore, this region of SEE is likely in close proximity of H V R -4 position 72. This constrains the possible conformations ofa trimolecular complex ( M H C -T C R -S E E ) and is most compatible with a position of SEE similar to that of SEB and TSST1 relative to M H C class II, e.g., adjacent to the c~ helix of the o~1 domain of M H C class II (30, 31) .
Discussion
This paper addresses three unresolved questions. (a) Do all SAGs, including bacterial (bSAG) and viral (vSAG), interact in the same way with T C R residues or not? (b) What is the relative position of the T C R within the tri-molecular complex and is it variable from one complex to another? (c) Do naturally occurring allelic variants of T C R BV genes differ functionally?
Variable SAG-interactive Sites on TCR ~ Chain. Generally, SAGs are thought to bind to the lateral surface of the T C R 13 chain and in particular to residues of the H V R 4 region. Positions 73/74 (adjacent to position 72 investigated in this study) were implicated by mutagenesis in binding of mBV8S2 to Mtv-7 vSAG (7) and in binding of mBV17 to Mtv-9 vSAG (9). H V R 4 was shown to impart specificity for the bSAGs SEC2 and SEC3 by molecularly transplanting 11 HVP-,4 residues of the reactive BV13S2 to the nonreactive BV13S1 which then acquired SEC2 and SEC3 reactivity (8). Thus, both vSAG and bSAG seem to focus on the T C R H V R 4 region.
Early studies with the vSAG of Mtv-7 showed that glycosylation of N residues 18, 20, and 74 ofmBV8S2 (16, 18 , and 71 in original reference) inhibited reactivity with Mtv-7 (7). However, several bSAGs showed equivalent dissociation constants for binding of glycosylated versus unglycosylated mBV8S2 in a recent BIAcore binding study (32) . Although Mtv vSAG were not examined in this study, the implication is that the vSAG of Mtv-7 may differ from bSAGs in terms of the T C R contact residues of mBV8S2 used.
Herein we show that a bSAG (SEE) and a vSAG (Mtv-9) differ in fine specificity for human TCRBV6S7. This T C R gene is naturally allelic. The vSAG of Mtv-9 stimulated both alleles equally well, but the bSAG, SEE, preferentially reacts with the BV6S7"1 allele. A monoclonal antibody, OT145, also has preferential reactivity with this allele. Although there are two amino acid differences between the two alleles, the single residue important for preferential reactivity of both ligands is position 72 (Fig. 1 ), at the apex of H V R -4 , right between 13 strands D and E at a sharp turn in the carbon backbone of the T C R [3 chain (3, 33) . BV6S7"1 encodes G72 and BV6S7"2 encodes a negatively charged E72.
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TCR Binding Differs for SEE and Mtv-9 SAG Figure 8 . Model of BV6S7*I and BV6S7"2 based on coordinates ofmBV8S2 beta chain (38) . 26 residues of the mouse beta chain variable region were substituted with the human sequence excluding the CDRIII region which was not altered. The coordinates were recalculated with the program Modeler (48). For both human BV6S7 proteins the carbon backbone closely overlaps that of the original mouse beta chain with the exception of $62 which represents a supplementary amino acid as the human BV6S7 sequences are one residue longer than the mBV8S2. The image was created with InsightlI and shows BV6S7"1 on the left and BV6S7"2 on the right; CDRI = green, CDRII = magenta, CDRIII = yellow, HVR4 = orange, E/G72 = white (with side chain). The side chain of N52 in CDRII and the exposed surface for CDR1, CDR2, and HVR4 are shown.
The difference in fine specificity between SEE and the vSAG of Mtv-9 means that each SAG interacts differently with the same T C R . In fact, others have described T C R BV mutations that affect different SAGs in opposite ways. For instance m_BV10 T26A resulted in diminished reactivity with SEC2 but not with ExT and L27A decreased reactivity with ExT but not SEC2 (34) . In the D10 T C R mBV8.2 N 2 4 H allows recognition o f Mtv-7 SAG and SEB, but wild-type N24 allows recognition of only SEB. In the same T C R G51V G53D allows recognition of SEB, but not SECI_3, which are all recognized by the wild-type T C R (35) . Finally, T C R ~3 chains expressing various BV genes, each known to provide for reactivity with the same SAG, do not share c o m m o n residues when comparing modeled structures based on the crystal structure o f the T C R (3 chain (32) . One explanation for these data is that there are several distinct binding sites for the same SAG depending on the T C R involved.
It is possible that there are subgroups o f SAGs that interact with T C R 13 chain in a similar way. Such distinct groups might include the group o f M t v vSAGs, the bSAGs with two M H C class II binding sites o f which one is Zn ++ dependent (e.g., SEA), or the bSAGs with a single M H C class II binding site (e.g., SEB, TSST-1). For instance SEA cross-links M H C class II molecules (36, 37) . W i t h SAG molecules on both sides o f an M H C class II molecule the position of the T C R may be constrained.
There are several possible explanations for the relative lack of reactivity o f BV6S7"2 with SEE and OT145. A simple hypothesis is that the shape o f the H V R 4 region is modified in the absence of a large charged R group at position 72. This was examined (Fig. 8 ) by comparing the modeled structure of the two human T C R BV6S7 alleles using the crystal coordinates of a mouse T C R ~ chain (38) . (Fig. 8 ).
Thus the reactive BV6S7"1 allele, encoding G72 (with just a hydrogen as a side chain), is characterized by a surface depression which could accommodate an SEE residue. BV8, the favored target o f SEE encodes A72, also with a very small side chain (CH3). In contrast, the depression is filled in BV6S7"2 with the charged side chain of E72 (CH2-C H 2 -C O O -). The oxygen atoms of E72 are potential electron donors, but the closest individual atoms, from C D R I (H24) or C D R I I (Q51), are at a distance of 3.36 A or greater. Thus hydrogen bonds and salt bridges are unlikely and E72 is probably fially charged at a physiological pH. An alternative hypothesis is that the critically located charge at E72 might result in electrostatic repulsion be- tween T C R [3 chain and the SAG. BV8, like BV6S7*I, does not encode a charged residue at the apex of the HVR4 region ( Table 2 ). The negative charge of E72 could prevent interaction with SEE due to a negatively charged SEE residue. Two amino acids of SEE that determine BV specificity have been mapped (17) (18) (19) . The SAGs SEE and SEA are closely related (82% identity) but have different BV specificities. Thus, SEA mutated at two residues (SEA $206P N207D) to emulate the sequence of SEE (Fig. 7) , resulted in gain of the BV8 and BV5S1 specificities of SEE. SEE has not yet been crystallized. However, a crystal structure of the related SEA (39) and a co-crystal of SEB (30) and TSST1 (31) with HLA DR1 have been described. The SAG structures are in general quite similar, in particular the region corresponding to SEE196_204 which represents a solvent exposed loop linking the [310 strand to the c~5 helix (39-41), see Fig. 7 . In the SEB-DR1 co-crystal structure (30) this loop protrudes such that it overlies the HLA DR1 0t helix of the c~1 domain (DR1 residues cx51-~x57) in a position where it could bind to T C R [3 chain residues. Using this model and assuming close proximity between residue E72 of the T C R [3 chain and residue D204 of SEE, the T C R [3 chain C D R I and C D R I I would be placed over the M H C or1 domain and the C D R I and C D R I I of the T C R a chain on the e~ helix of the M H C [31 domain consistent with some models of T C R / M H C positioning (42, 43) . However, a recent model of T C R positioning, based on recognition of variant conalbumin peptides presented by IE k (44), places the T C R [3 chain and HVR-4 over the COOH-terminal portion of the peptide which is inconsistent with binding to known SAG T C R interaction sites and the SAG/DR1 co-crystal data. If these results are generally valid for nominal A g / M H C recognition, it follows that the rotational orientation of the T C R differs between A g / M H C versus SAg/MHC recognition. In addition, it is likely that the axial orientation of the T C R differs because SAGs, specially TSST1 (31), occupy space above the class II c~ helix of the a l domain and thus are probably wedged in between T C R and M H C on one side. This is consistent with our data, as position 72 of H V R 4 would lie on top of SEE D204 in stead of making contact with M H C class II residues (Fig. 9) .
Other TCR Regions That Contribute to SAG Recognition. The actual T C R residues of BV6S7*I that mediate binding to SEE probably include additional residues beyond residue 72, because the HVR4 motif ERTGGxxST68_76 is shared with BV16 (Table 2) which is neither SEE, Mtv-9 or OT145 reactive (3, and data not shown). Moreover, reactivity of OT145 and SEE with BV6S7 is not completely inhibited in the presence of E72. Thus the interaction between T C R HVR-4 and these ligands is presumably more complex and involves T C R residues other than position 72.
T C R residues implicated in SAG reactivity by mutagenesis experiments generally do not affect A g / M H C reactivity, and vice versa (45) . However, from studies of SAG/ T C R combinations of presumed "lower affinity," where an effect of the presenting M H C class II is readily seen, it has become clear that residues beyond HVR4 and the lateral surface of the T C R [3 chain are involved in determining SAG reactivity, such as residues in T C R [3 CDRI-III (10, 11, 13, 14, 34) and residues of the T C R oL chain (46, 47) .
It is therefore important to avoid drawing conclusions based solely on experiments with transfected T cell clones in which a single T C R is expressed. SEE has low reactivity with BV6S7 TCRs (compared with BV8) and it was therefore useful to confirm the transfectant data ( Fig. 1) with an assay using polyclonal T cells from heterozygous donors. The R T -P C R assay described for detection of BV6S7 alleles (Fig. 6) has not been previously used to monitor SAG responses. Results are independent of all other T C R variable gene segments (BD, BJ, AV, AJ) used by T cells responding to the SAG, because polyclonal T cells are used. Any possible effect of M H C alleles (25) 
